v3.26.3
Note 8 - Segment Information
 3 Months Ended
Jul. 31, 2026
Notes to Financial Statements  
Segment Reporting [Text Block]

Note 8. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM in deciding how to allocate resources and in assessing performance. The Company has determined that its CODM is its Chief Executive Officer.

 

Management and the CODM view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing and commercializing products and AI-ECG solutions in the cardiovascular diagnostic technology field. The CODM uses operating expenses to measure performance against progress in its clinical trials and its product development. The Company's CODM reviews and evaluates the total net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

 

The following table summarizes the segment's financial information including the Company's significant segment expenses:

 

  

Three Months Ended July 31,

 
  

2026

  

2025

 
         

Gross Margin

 $1,340  $1,140 

Segment operating expenses:

        

Clinical and regulatory

  182,362   190,896 

Research and development

  681,380   764,803 

Operations

  42,887   41,507 

Sales and marketing

  159,729   86,942 

General and administrative

  1,874,072   791,111 

Loss from operations

  (2,939,090)  (1,874,119)

Other income (expense):

        

Interest expense

  (235,261)  (183,688)

Other income

  2,007   2,813 

Total other expense

  (233,254)  (180,875)

Net loss

 $(3,172,344) $(2,054,994)